Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer

Area of Science:

• Oncology
• Medical Research
• Clinical Trials

Background:

• Controversies exist regarding the optimal management of EGFR-mutant non-small-cell lung cancer (NSCLC) with brain metastases (BMs).
• Treatment options include EGFR tyrosine kinase inhibitors (TKIs), chemotherapy, and various radiation therapies (RTs), but optimal combination and sequencing are debated.
• The role of upfront versus deferred local therapies and systemic treatments remains unclear.

Purpose of the Study:

• To evaluate the efficacy of sequential therapies including EGFR-TKIs, RT, and chemotherapy in EGFR-mutant NSCLC patients with BMs.
• To compare survival outcomes based on treatment strategies and EGFR mutation types.
• To identify prognostic factors influencing overall survival in this patient cohort.

Main Methods:

• A cohort of 45 EGFR-mutant NSCLC patients with BMs received sequential EGFR-TKIs, RT (whole-brain or stereotactic radiosurgery), and chemotherapy.
• Patient follow-up extended until February 2017, with data analyzed using Kaplan-Meier and Cox regression methods.
• Treatment response and survival data were collected and analyzed to assess outcomes.

Main Results:

• Median overall survival (OS) was 28 months.
• Patients with EGFR exon 19 deletion showed a trend towards longer median OS compared to exon 21 L858R mutation (not reached vs. 26.5 months, P=0.0969).
• No significant difference in OS was observed between upfront RT and deferred RT groups (P=0.57), nor between first-line chemotherapy and EGFR-TKI groups (P=0.499). Prognosis correlated with EGFR mutation type (P=0.017).

Conclusions:

• EGFR-mutant NSCLC patients with BMs benefit from combined and sequential therapies involving EGFR-TKIs, chemotherapy, and RT.
• EGFR exon 19 deletion may be associated with improved overall survival.
• The optimal timing for radiation therapy requires further investigation.